| Eligibility Criteria: |
Inclusion Criteria:
- Subjects must have chronic plaque type psoriasis that, in the investigator's opinion
is clinically stable and does not require urgent treatment with standard, FDA approved
psoriasis therapies.
- Psoriasis must cover at least 6% of subject's body surface area and lesions must have
moderate plaque thickness
- Subjects must be willing to and have the capacity for giving written informed consent
- Ages 18 to 75
- Subjects must be available for the total duration of the study (16 weeks)
- Female subjects that are sexually active with male partners must be postmenopausal,
surgically incapable of childbearing, or be using a medically acceptable method of
contraception throughout the entire study period. Medically acceptable methods of
contraception that may be used by the subject and/or partner include oral
contraceptives or patch, diaphragms with spermicide, IUD, condom with spermicide, or
progestin implant or injection. Females taking oral contraceptives must have taken
them consistently for at least two months prior to receiving study medication. All
female subjects must consent to a urine pregnancy test at screening and at start of
study, which must be negative at both time points. Male subjects who are sexually
active with female partners and are capable of fertilization must ensure that their
female partners will either be postmenopausal, surgically incapable of childbearing,
or will use a medically acceptable method of contraception throughout the entire study
period
Exclusion Criteria:
•Females subjects who are pregnant or nursing a child •Subjects who are sensitive to or
allergic to turmeric or curry powder •History of alcohol or drug abuse within 12 months of
screening visit •Subjects with rapidly improving or deteriorating psoriasis or the
following more variable types of psoriasis: guttate, erythrodermic, or pustular psoriasis
•Use of systemic treatments for psoriasis (including methotrexate, cyclosporine, alefacept,
adalimumab, efalizumab, infliximab, etanercept, etretinate, systemic steroids and PUVA)
within 3 months prior to day 0 or at any time during the study. •Use of topical treatments
and UVB therapy for psoriasis (not including non-medicated emollients or shampoos) within
14 days prior to day 0 or at any time during the study period. •Subjects, who have received
an experimental drug, used any experimental medical devise within 30 days prior to
screening •Clinically significant laboratory abnormalities •Subjects with significant
medical comorbidities •Subjects for whom the dose of the following medications has changed
within 1 month of day 0: clonidine, digoxin, beta-blockers, lithium, or anti-malarials
•Subjects unable to swallow pills •Subject who are unable to adhere to the protocol for any
reason
|